Abstract #2107

1H-MRS Study of Secondary Progressive MS Patients Followed Over 2 Years in the Dirucotide (MBP8298) Placebo Controlled Study

Madeleine Hodgson¹, Cornelia Laule^1,2, Irene Vavasour^1,2, David Li², Yinshan Zhao³, Tony Traboulsee³, Joel Oger³, Alex MacKay^1,2

¹Physics, University of British Columbia, Vancouver, British Columbia, Canada; ²Radiology, University of British Columbia, Vancouver, British Columbia, Canada; ³Medicine, University of British Columbia, Vancouver, British Columbia, Canada

1H-MRS is a useful technique for evaluating demyelination and axonal integrity and thus can be used to monitor disease progression in Multiple Sclerosis (MS). Dirucotide (MBP8298) has exhibited potential as a treatment for Secondary Progressive MS (SPMS) to slow disease progression. The effects of Dirucotide were investigated using 1H-MRS in a single centre, double-blinded MRI substudy with a placebo control. There is no change observed in important metabolites in either of the cohorts over a two-year period, which is perhaps not surprising given that Dirucotide did not meet primary endpoints in the MAESTRO-01 Phase III trial.